Take a Brain-check with The Mind Makeover Retreat™
Change your life in ways you may never have thought possible on The Mind Makeover Retreat™, the latest pioneering retreat launched by Health and Fitness Travel, the wellness holiday specialists. Led by international master of mind-improvement and celebrity coach, Steve McKeown, this ground-breaking wellness retreat promotes positive mental well-being and launches this September at the luxurious Macdonald Monchique Resort & Spa, in the western Algarve.
A healthy mind lives in a healthy body and mental health is imperative for physical well-being. It’s estimated that 1 in 4 adults in England experience mental health problems in any given year. With longer working hours and increasing pressures, both professionally and personally, mental health issues are more prevalent than ever. This unique psychological programme works by combining state-of-the-art tools to improve your personal and professional performance, and achieve your full potential.
Whether you suffer from anxiety, brain fog, weight or sleep issues, lack of direction, or are simply in need of a recharge, this life-changing retreat will break down the barriers that are keeping you from success, and kick-start your journey to becoming your best self. Unmanaged thoughts adversely affect our energy and physical health and the connection between our brain and immune system is proven; not managing your thinking and beliefs is detrimental to your health and well-being.
Speaking about the motivation behind The Mind Makeover, Steve McKeown says; “I wanted to design a retreat with Health and Fitness Travel that is unique and has never been available before, a retreat that will not only be extremely relaxing and fun but will enable you to regain control of your cognition, challenge your assumptions and rid you of those limitations that have held you back in your life. Being away from the distractions and stresses of normal daily life that can sometimes cause restraints, makes our retreat at Macdonald Monchique the perfect environment for change”.
Macdonald Monchique Resort and Spa is beautifully secluded amid lush green woodlands and towering mountains in the western Algarve. This ever-sunny destination offers breath-taking panoramic coastal and alpine views away from busy built up tourist areas and is near stunning beaches and the beautiful old village of Monchique. The Mountain of Monchique is the region's favourite mountain for hiking in nature.
Retreat participants will have full access to Macdonald Monchique’s luxury spa facilities, four dynamic restaurants, invigorating group therapy work, a personal spa treatment and group fitness activities. Guests may wish to partake in complimentary daily activities including dance and aqua-fun or enjoy a morning walk surrounded by stunning views of the coast and mountains, or simply unwind in the elegant and tranquil environment.
A seven-night break at Macdonald Monchique on The Mind Makeover Retreat costs £2,385pp based on 2 people sharing, or £2,750pp for single occupancy. Price includes accommodation, full board, return flights, private transfers and The Mind Makeover programme.
Zogenix is set to become a key player in the epilepsy market following positive results for ZX008, says GlobalData
Zogenix’s positive results for its drug ZX008 (fenfluramine hydrochloride) and the subsequent approval that is likely to follow, will push Zogenix to become a key player in the epilepsy market, according to GlobalData, a leading data and analytics company.
Zogenix will treat young children and adolescents suffering from Dravet syndrome. The results will allow Zogenix to push ahead with its plan to submit regulatory filings in the US and EU markets in Q4 2018, swiftly following GW Pharmaceutical’s Epidiolex (cannabidiol).
GlobalData’s report: ‘PharmaPoint: Epilepsy – Global Drug Forecast and Analysis to 2026’, highlights that Dravet syndrome is a rare form of pediatric epilepsy that has proved difficult to treat, with current therapies showing poor efficacy, safety, or tolerability profiles. As such, treatments for this form of epilepsy are one of the more significant needs in the epilepsy market.
Rahael Maladwala, Pharma Analyst at GlobalData, comments: “Moving forward, the company has stated that it expects to file a regulatory submission in the US and EU by the end of the year, with a view to launch by the end of 2019.
“However, with trials also running in patients suffering from Lennox-Gastaut syndrome (LGS) and the epilepsy market lacking effective therapies, it is likely that Zogenix will continue to file for approval in other epilepsy patient populations after Dravet syndrome.”
The timing of ZX008’s approval will likely elicit competition with GW Pharmaceutical’s Epidiolex, which was approved by the FDA last month for the treatment of Dravet syndrome and LGS patients. While Epidiolex has already been approved in the US, the molecule has a controversial mechanism of action, as it is a pure extract from cannabis. Consequently, Epidiolex has to overcome further regulatory hurdles set by the Drug Enforcement Agency (DEA), which will delay its launch.
Maladwala adds: “ZX008 has already been used in a compassion program in Belgium, and therefore has proven efficacy in a real-world setting, which may sway the decision of some physicians. Realistically, the high unmet need for effective treatments in pediatric epilepsies such as Dravet syndrome and LGS mean that both drugs will likely experience a quick uptake and command a large market share in these patient populations.
“All that remains to be seen now is whether or not the company can formulate an effective marketing strategy as well as a favorable pricing and reimbursement position that will maximize sales of ZX008 and encourage its uptake over Epidiolex.”
Morneau Shepell opens crisis line to support those affected by Toronto's Danforth shooting
Company's 24/7 free crisis hotline available now to those in need: 1.844.751.2133
TORONTO, July 23, 2018 /CNW/ - As a result of the tragic shooting that occurred in Toronto's Greektown neighbourhood on Sunday, July 22, Morneau Shepell has opened its 24/7 bilingual crisis support hotline to help anyone affected by the traumatic event.
"Our deepest sympathies and thoughts are with the families and loved ones of the individuals who lost their lives, and our thoughts continue to be with the Greektown community as they cope with yesterday's tragic event," said Stephen Liptrap, president and chief executive officer, Morneau Shepell. "The Danforth, and all communities across Toronto, should be a place where people feel safe to enjoy an evening with friends and family. As a part of this vibrant city, we're devastated by the recent spike in gun violence and are committed to helping those affected. As such, we have opened our free 24/7 bilingual crisis hotline and encourage those seeking support to reach out."
A crisis or traumatic event can trigger overwhelming emotional responses. Morneau Shepell's national 24/7 crisis support line offers professional emotional support to anyone in crisis. When calling the crisis line, individuals receive crisis counselling support and/or referral to community resources. Anyone affected by the incident in Toronto can reach the free crisis support line at 1.844.751.2133.
The Company's employee assistance program is also available to existing clients through the designated toll-free number or by visiting workhealthlife.com.
About Morneau Shepell
Morneau Shepell is the only human resources consulting and technology company that takes an integrated approach to employee assistance, health, benefits and retirement needs. The Company is the leading provider of employee and family assistance programs, the largest administrator of retirement and benefits plans and the largest provider of integrated absence management solutions in Canada. As a leader in strategic HR consulting and innovative pension design, the Company helps clients solve complex workforce problems and provides integrated productivity, health and retirement solutions. Established in 1966, Morneau Shepell serves approximately 20,000 clients, ranging from small businesses to some of the largest corporations and associations. With more than 4,000 employees in offices across North America, Morneau Shepell provides services to organizations across Canada, in the United States and around the globe. Morneau Shepell is a publicly-traded company on the Toronto Stock Exchange (TSX: MSI). For more information, visit morneaushepell.com.
SOURCE Morneau Shepell Inc.
Tesco’s new discount chain is a risky response to Aldi and Lidl, says GlobalData
Following speculation that Tesco is to launch a new discount fascia in the UK to compete with Aldi and Lidl,
Thomas Brereton, Retail Analyst at GlobalData, a leading data and analytics company, offers his view on the fascia’s potential:
‘‘The possibility of Tesco opening a discount fascia in a bid to neutralize the growing threat posed by German discounters Aldi and Lidl looks a bold move, but orchestrating the emergence of a new brand without damaging the reputation of the main Tesco image will require pinpoint precision to succeed.
"Since 2008 Aldi and Lidl have increased their combined market share from 2.9% to 9.4%, at the expense of Tesco and the rest of the Big Four, who have all struggled to respond. There are two issues Tesco must consider carefully: the longevity of the project given the scale necessary to make such a discount fascia profitable, and disrupting sales at the main brand through an erosion of brand image. Sainsbury’s attempted a similar concept in 2014 through a partnership with Netto, and its closure two years later came as a result of their failure to expand quickly or sizeably enough.
"Tesco could face a similar issue down the road; reports of an initial 60 stores would be a promising start, but expanding this to the couple of hundred or more needed for viability (without taking too many sales from existing Tesco locations) will be challenging. With its relationship with Booker and new association with European giant Carrefour, Tesco will feel that the buying power it now wields will be enough to make this a success.
"Tesco last tried the discounter approach in the mid-80s under Victor Value. As with Sainsbury’s-Netto it was eventually abandoned – blamed on the undermining of the main Tesco brand. CEO Dave will be keen to avoid a déjà vu, and may feel that the price-led customers of 2018 will not be as discriminating against own-label products as shoppers were 30 years ago.’’
Opening the medicine cabinet or make-up drawer to behold a littered mosaic of creams, mascaras, brushes, and the like, many of us face the realization that we are product junkies! Of course, a refined and minimalist approach to beauty is ideal, but where to start?! Deciding what to keep, what to toss, and what can be salvaged is a daunting project. Beauty and Wellness Expert June Jacobs, CEO and Founder of June Jacobs Skin Care, has curated The Beauty Deep Clean Checklist to make the process effective, straightforward, and supremely relieving.
“The thoughtful decisions you make about your products are just as critical as the rituals you do to reset the mind and body. Edit the items on your shelf that no longer serve your skin. Not only will you feel lighter, you'll probably also end up with a skin care regimen that's more personalized, targeted, effective and safe.” - June Jacobs
Keep your product collection fresh and effective with June Jacob’s three simple rules:
RULE #1: Keep an eye on the PAO!
Always look for the PAO (Period After Opening) symbol on your product. The little symbol is provided by manufacturers based on individual stability testing. Keep a Sharpie in your makeup bag to mark your opening date. Once the PAO has passed, it’s time to toss the product as it is no longer effective.
RULE #2: Keep your brushes clean!
Washing your makeup brushes once a week will minimize oil and germ transfer. Follow this process to maximize cleanliness:
- Use lukewarm water and baby shampoo to gently wash bristles in the palm of your hand.
- Rinse.
- Squeeze out any excess water.
- Allow brushes to air dry.
RULE #3: If you can’t remember the last time you used it, let it go!
Product lifespans often depend on the area of application. Mascara and skincare applied around the eyes should be changed frequently. Also keep in mind that packaging impacts the lifespan of your skincare. Anything that you take from the jar with your fingers is at a higher risk for contamination. Once a jar has been opened, it should not be kept for more than six months, max 1 year. Depending on the componentry, the product will be more or less susceptible to oxygen, bacteria formation, and increased speed of aging the product. For example, lotions with an airless pump are protected from the elements and last longer.
Over the counter (OTC) products are FDA regulated and have an expiration date. Of course, for your safety, we recommend you throw away any products that have passed the expiration date.
When to throw out:
ABOUT JUNE JACOBS
June Jacobs became a trailblazer of the contemporary approach to skin care using her personal life traditions and her 30+ years of professional experience to create her namesake brand, June Jacobs – leading the charge by combining cutting-edge science with botanical remedies for a luxuriant experience. To create this groundbreaking line, June opened her own lab so that she could truly focus on overseeing the creation of botanically based products that delivered results.
Coming from a large extended family steeped in Mediterranean tradition, June was captivated as a child by the myriad of uses from the ingredients local to her family's ancestral home on the coast of the Caspian Sea. June observed the resourceful and beautiful women in her family utilize anti- oxidant rich ingredients for healing and beauty remedies as well as overall well-being. Using remaining leaves from the daily tea infused into creams that were applied to their skin was the norm.
Along with these passed down traditions was the influence of physicians, inventors and merchants within her large family. From them, she learned the importance of science, practical application and technological innovation. June began her career as a consultant working in the offices of several esteemed dermatologists and plastic surgeons. Instinctively, June knew there had to be a way to leverage science with the natural ingredients used by the lineage of the beautiful women in her family for generations.
As a single mother, putting her only child, Rochelle, through college, June was able to sustain her lasting relationships with patients and as a result, her reputation grew. Some of New York City’s finest cosmetic surgeons and dermatologists were now retaining June to help build their own clinical skin care products for their practices.
Never satisfied with what was available in the market at this time or even with what she had assisted these doctors in developing, June took her experiences and concluded it was time to go out on her own to execute her dreams and visions. She partnered with Rochelle, now a businesswoman and self-confessed skin care junkie, to launch their own collection of luxury skin care products.
June and Rochelle are committed to evolving advanced formulas with natural ingredients while staying true to the enduring traditions handed down from their family and culture.
IMBA - Institut für Molekulare Biotechnologie GmbH: Growing Brain Cancer in a Dish
For the first-time, researchers at IMBA - Institute of Molecular Biotechnology of the Austrian Academy of Sciences - develop organoids, that mimic the onset of brain cancer. This method not only sheds light on the complex biology of human brain tumors but could also pave the way for new medical applications.
VIENNA, July 23, 2018 /CNW/ - Brain tumors are among the most aggressive and deadly cancers and a leading cause of cancer-related death in children and young adults.
Glioblastoma is a particularly aggressive form of brain tumor that is characterized by a very rapid tumor growth of glia cells - the most abundant cell types in the central nervous system, that surround and support neurons. The tumor is notoriously difficult to treat as it forms tentacle-like structures, that makes it difficult to remove the tumors surgically. Also, glioblastoma tend to liaise with blood vessels, helping cancerous cells to grow and spread very quickly. With each cell division, they accumulate mutations that can render them resistant to drugs. Because of the molecular characteristics of the human brain, it has been very difficult for scientist to find a suitable model organism to study brain cancers.
Organoid technology could now lead to a paradigm shift in studying glioblastoma and other forms of brain cancers. In recent years, researchers have managed to develop more and more lab grown organ like structures, or organoids. Already in 2013 Jürgen Knoblich and his team at IMBA were the first ones to use brain- organoids from iPS cells for studying molecular and developmental characteristics as well as neurological diseases of the human brain. Now, they have succeeded to grow one of the deadliest cancers, brain cancer, in a dish. The novelty: this method allows the researchers to replicate the process of brain carcinogenesis in a dish, where they can observe brain cancer onset already at its early stages and watch the brain-organoid growing a tumor in a dish.
In a publication in the current edition of the journal Nature Methods the group reports on the new neoplastic cerebral organoids they have developed to study brain tumors. These organoids faithfully reproduce unique aspects of the human brain, such as its diverse cell types and the stages by which it develops, allowing scientists to get a handle on the ways tumors arise, and also provide a system to try out new cancer therapies. "For the first time, we established a human model for brain cancer to rapidly test or screen for the tumorigenic potential of gene mutations found from cancer genome sequencing projects. Using genome-editing techniques, we introduced clinically-relevant mutations into the cerebral organoids. With this method, we are trying to mimic the brain tumor onset in vivo by only mutating a very small population of cells," explains Shan Bian, postdoc at IMBA and first author of the study.
Over the past few years, huge cancer genome sequencing projects have catalogued thousands of mutations found in patient tumors. Such genetic defects arise through natural mistakes in the copying of DNA, through the consumption of carcinogens or other causes. They trigger fundamental changes in healthy cells that cause them to spin out of control, reproducing at an astounding pace. Each time such a cell divides it may generate new mutations, leaving scientists with a huge puzzle to assemble. The novel brain-cancer or neoplastic organoids now offer a means to investigate, how some of these mutations are driving forces in tumors, crucial in triggering the onset of cancer, and necessary to address through treatments, while others are simply side effects.
From bench to bedside
The scientists carried out studies of these miniature tumors to identify additional changes they had undergone, identifying new markers that may help in diagnosing the disease and classifying the tumor a patient has.
Once a tumor has developed, the scientists can target a specific mutation to determine whether the defect is also essential for the long-term survival of the tumor. Any change that causes it to shrink or disappear makes a good candidate for future therapies.
The scientists tested this principle by applying a drug called Afatinib, which is currently being used in clinical trials as a treatment for glioblastoma. They found that after 40 days, administration of the drug significantly reduced the number of tumor cells in two combinations of mutations, but not in the third or in cells with too much MYC. Afatinib inhibits a molecule called EGFR - which is specifically overexpressed in those two types of tumors. When testing four additional EGFR inhibitors used in therapies, a drug called Erlotinib significantly reduced the number of tumor cells as well, while the effects of others were minimal.
"These results show that brain organoids also have significant impact for cancer research and public health. We can now develop organoids from brain tumor patients allowing us to test the efficacy of different combinations of therapies," says stem cell pioneer Knoblich, who is interim director of IMBA. "As a next step it will be important to foster clinical partnerships, so we can work towards translating our findings from the bench to the bedside."
Publication: Bian et al., 2018, 'Genetically engineered cerebral organoids model brain tumor formation', Nature Methods; doi: 10.1038/s41592-018-0070-7
NEW PRODUCT: WEDGIE 90/90 CUSHION FOR BACK PAIN
(Patent Pending Serial No. US 29/572,234)
Hudson Valley, New York. Physical therapist Dr. Christian Campilii at the Center for Physical Therapy notes “Oh, when my patients’ backs go out, I start with lying them down on a floor in the 90/90 position with a WEDGIE cushion. These sufferers gleam with excitement and can attest that this is the only pain free position “when their back goes out”.
World Problem: Four out of five world citizens currently have or will have a significant spinal problem at some point in their lives. This is true in every country. Back pain can fully debilitate a person, stopping them from walking, even breathing properly. Many more people are suffering with a low-grade ache, or numbness in the arms or legs. People are living their days with aches and pains wishing to have better health and quality of living. They want better days with their family or loved ones, at the workplace, during activities of daily living, and in extracurricular activities they truly enjoy.
Origins of the WEDGIE: After 20 years of recommending pillows, cushions and pads, physical therapist Dr. Christian Campilii embarked on a project to properly design a cushion to help people with back pain. Using a design team and many tested iterations they produced the WEDGIE which is patent pending. Dr. Christian Campilii has tested his design with thousands of patients in the Hudson Valley, New York.
Science: Recent research on astronauts has shown that there are changes within the spinal disc spaces that vary depending on time of day and hydration levels. Jeffrey C. Lotz, PhD the David S. Bradford, MD, Endowed Chair in Orthopedic Surgery and vice chair for research at the UCSF Department of Orthopedic Surgery performed studies and discovered that with gravity, when standing, our spine is vertical, and the discs become compressed. The water is squeezed out of the disc spaces. He found that over the course of the day, the height of the disc spaces diminishes, the curvature of our spines changes, and our spinal flexibility is increased. When we sleep, however, as we go horizontal, then gravity is removed, and hard discs rehydrate due to their inherent ability to take on water and swell. Disc height and stiffness are recovered.
Studies have shown that runners who lie in the 90-90 position for 30 minutes daily are able to run and function with much less back pain. Athletes are encouraged to rest in 90/90 to counter the effects of running and jumping.
DESIGN RATIONALE: The WEDGIE is a spinal cushion whose unique shape and exact dimensions is primarily used to raise one’s legs to take the pressure off the lumbar spine. This product is durable and transportable so that one can travel and then maintain the position. It can be inflated and deflated to adjust to a person’s height. The WEDGIE is used in physical therapy settings, hospitals and in homes.
The benefits are as follows:
- Relieves back pain
- Opens up the spine to reduce pressure on the nerves
- Decreases muscle spasms by relaxing major lumbar muscles such as the PSOAS and the QUADRATUS LOMBORUM
- Re-hydrates the lumbar spine discs
- Relaxes the joints of the hips, knee, and ankle
- Reduces the tension of the upper body, including shoulders and neck
ENDORSEMENT: Spinal Surgeon, Dr. Ken Hansraj opined: “When the patients are rehabilitating after spine surgery, then my treatment is then placed in the hands of the physical therapists. My patients have responded very positively and are very thankful for the treatments rendered by Dr. Christian Campilii. The patients rave about the 90/90 position and the WEDGIE Cushion”
AVAILABILITY:
The WEDGIE Cushion is available at www.GOWEDGIE.com
Interested Media may contact us for a demo
About Dr. Christian Campilii
Dr. Christian Campilii is a renowned physical therapist who was born and raised in the Hudson Valley. He is well recognized by the local sport teams and clubs. He is the chairperson for the executive committee at Marist College’s doctorate program in physical therapy. He serves on the board for schools in Mexico City for underprivileged children.
Dr. Campilii has a spine book and several other human performance products coming to the market in the next year.
Dr. Campilii is a graduate of Notre Dame and an avid football fan. He owns and runs clinic for the athletes and faculty at Marist and Vassar Colleges. He has employed over 10 athletic trainers in the local high schools and thoroughly loves challenging the athletes. He is currently the owner of 5 physical therapy practices and prides himself on the quality of care.
When not acting as an inventor or a physical therapist, Chris enjoys spending time with his family. He continues in his love of travel, skiing, mountain biking and hiking.
IAS 2018: Beckman Coulter Life Sciences Announces First Global CARES HIV/AIDS Award Winner
Recognizes 'care, dedication and commitment' of ordinary people
AMSTERDAM, July 23, 2018 /CNW/ - A 28-year-old African community youth worker Evah Namakula, has won the first CARES HIV/AIDS award, recognizing ordinary people who show 'care, dedication and commitment' in their communities in the fight against the disease. Ms Namakula is part of the 2018 global award launch at the International Aids Society meeting, Amsterdam (23-27 July), booth #407. CARES Media Information.
The first award focused on the dedication of ordinary people in Africa, an area most affected by HIV/AIDS. It has two categories - Ms Namakula (individual) and an organization, Hillcrest AIDS Centre Trust (HACT), a South African charity caring for disadvantaged people. The organization receives a grant of $5500 USD from Beckman Coulter Life Sciences through the Beckman Coulter Foundation. This is made in the name of the individual winner, but their work cannot be linked.
An independent judging panel described as 'remarkable' Ms Namakula's achievements in her local Ugandan community to dispel the stigma of HIV/AIDs. She is also global youth ambassador for Reach Out Integrity (ROI) Africa, promoting health and sexual responsibility to young people - and has founded her own charity, IGNITE . Evah is part of the Young African Leaders Initiative (YALI) set up by President Barack Obama to empower leadership skills in African youth. As a YALI volunteer, she has been a leadership mentor in local communities and schools, developing public speaking skills.
Inspired by the determination of her mother and siblings, Evah said: "l was already a campaigner but it was while working in my local hospital laboratory that I realised how I could use my medical knowledge to help reduce the myth young people in my community had about HIV/AIDS."
"Evah is an inspirational young woman and will be a hard act to follow," said Samuel Boova, Beckman Coulter's Director Alliance Development, High Burden HIV Markets. "She is exactly the kind of youth leader that President Obama wanted to encourage to develop the Africa of the future. We are honored not only to have her as our first winner, but to have her support in launching the global initiative.
"The award gives a platform to the work of unsung heroes, people who have shown individual dedication, commitment and courage or who have made a difference in the battle against HIV/AIDS."
SOURCE Beckman Coulter Life Sciences
|
| Vivier Pharma and The Publicist Group Team Up to Showcase ‘The Beauty of Results™’
The Publicist Group (TPG) continues to put its best face forward, adding Vivier Pharma to its roster of clients. TPG won the coveted Canadian, family-owned skin care company to support its brand relaunch, as well as educate media, consumers and skin care professionals on Vivier’s commitment to “The Beauty of Results™” through innovative products with proven formulas.
Vivier creates premium pharmaceutical skin care products that are proven to prepare, target, moisturize and protect your skin while delivering optimal results. Invested heavily in research and development while carefully hand-selecting key active ingredients, Vivier ensures its products are at the forefront of science to deliver the right solution for your unique skincare needs. Products and programs for all ages and skin care needs include a new discovery, first-to-market, anti-aging line, “GrenzCineä”. The “GrenzCineä” line includes powerful and ground-breaking antioxidants and anti-aging products that leave skin beautiful, more luminous, plumper and healthier-looking from the inside out. Quality is built with precision and care.
“We put the consumer at the heart of everything we do, and once they experience a physical and emotional transformation through the difference our skin care solutions provide, they are truly empowered to look and feel their best,” said Jess Vivier, Founder and CEO of Vivier Pharma. “We’re excited to continue to share our brand story and new brand aesthetic across Canada while delivering “The Beauty of Results™” alongside Toronto-based PR agency, The Publicist Group.”
TPG, Canadian communications agency, will manage all PR initiatives, including traditional media relations, influencer marketing, content creation and community management for Vivier, as well as support the brand through its relaunch and new product releases.
About Vivier Pharma
Vivier was founded in 1997 when Vitamin C was widely regarded as the anti-aging gold standard, though it oxidized quickly. Founder Jess Vivier understood that consumers wanted a high-quality serum that delivered on its promises while remaining stable to prevent and correct visible signs of aging. He patented the brand’s first L-Ascorbic USP serum that quickly gained success in the medical community. Today, Vivier has grown to a full range of proven skin care products to address and support various skin types and concerns in order to empower consumers to look and feel their best through “The Beauty of Results™”.www.vivierskin.com
About The Publicist Group
The Publicist Group is a full-service communications agency located in Toronto. Opening its doors in 2014, TPG offers an array of services from digital strategy, PR and marketing to events, influencer programs and content creation. Clients have included: First Canadian Place, Genuine Health, Hamilton Watch, Active Escapes, Viviscal, Toppik, Walter Craft Caesar, Princess Margaret Cancer Foundation, Roots, Loding, Watch It!, Denham, Ca Va De Soi, and many more. The TPG team executes 360-degree strategies; delivers original, creative and result-driven campaigns; and loves to make noise across the country with its clients’ initiatives. www.publicistgroup.com |
|
Club Med reveals name of much anticipated Canadian project, Club Med Québec Charlevoix
Construction on track for Club Med's first ever
all-inclusive, four-season mountain resort
MONTRÉAL, QC – Club Med’s executive committee, including 11 members representing worldwide markets, gathered today in Montréal for their quarterly meeting to unveil advancements in the brand’s business developments and global strategy. Amongst these announcements, the global leader in all-inclusive vacations revealed the name of Canada’s first-ever Club Med Village: Club Med Québec Charlevoix. Set to welcome guests in December 2020, construction has commenced at the Québec mountain resort.
President of Club Med, Henri Giscard d’Estaing shared this announcement alongside President and CEO of Club Med North America, Xavier Mufraggi, and Senior Vice President of Club Med Canada and Mexico, Carolyne Doyon. The all-inclusive pioneer has witnessed exceptional growth in recent years and aims to open five resorts per year. The company also has plans to execute major renovations to its current resorts to offer new and refreshed experiences.
“On behalf of the entire Club Med team, I’m delighted to welcome Canada in to our product portfolio,” says Henri Giscard d’Estaing, President of Club Med. “In naming Club Med Québec Charlevoix we wanted to not only shine a light on the province of Québec but the incredible region of Charlevoix itself and contribute to its worldwide influence. We are proud to expand our presence to this exceptional area, home to breathtaking landscapes, fine cuisine and thrilling ski areas.”
With 42,000 travellers to a Club Med village in 2017, Canadians can count themselves amongst Club Med’s dedicated clientele. These numbers will witness a sizable increase leading up to the launch of Club Med Québec Charlevoix. Canadians and international visitors alike can look forward to the following:
- 4-Trident Village with Exclusive Collection Space
- The first-ever four-season Club Med Village
- Only one hour from Québec City International Airport; in Charlevoix; with superb views of the St. Lawrence
- An experience inspired by Québec, presenting the beauties of the region and its unique culture
- A destination for families, couples and groups from different international regions
- Further information to be shared by the end of 2018
With this expansion, as well as the highly anticipated launches of Arcs Panorama (France) in December 2018, and Club Med Miches Playa Esmeralda (Dominican Republic) in December 2019, an Exclusive Collection Resort settled in a secluded, untouched natural area, Club Med is poised to retain its title as the worldwide leader in premium, all-inclusive vacations for families, active couples and solo travellers around the world.
About Club Med
Club Med, founded in 1950, is recognized as the pioneer of the all-inclusive market, offering 70 premium resorts in stunning locations around the world including North and South America, Caribbean, Asia, Africa, Europe and the Mediterranean. Established in 26 countries across five continents, the group employs more than 23,000 employees comprised of 110 varied nationalities. Club Med has had a corporate presence in Canada for over 40 years and employs a staff of more than 50 team members in their Montreal head office.
